GGrantIndex
Sort

48,018 grants matching immunotherapy

Core B: Computational

$413,235
Alan S Perelson · Beth Israel Deaconess Medical Center · P01 · FY2019 · AI

Metabolic Control of Immune Suppression in Gliomas

$413,173
Maciej S Lesniak · Northwestern University At Chicago · R01 · FY2018 · NS

Metabolic Control of Immune Suppression in Gliomas

$413,173
Maciej S Lesniak · Northwestern University At Chicago · R01 · FY2019 · NS

Transplant EBV Disease: Pathogenesis and Immunotherapy

$413,164
David T Rowe · University Of Pittsburgh At Pittsburgh · P50 · FY2007 · HL

Molecular Genetic Analysis of Mycobacterium tuberculosis

$413,135
Albert Einstein Col Of Med Yeshiva Univ · R37 · FY2005 · AI

TECH Core

$413,131
Kevin William Eliceiri · University Of Minnesota · U54 · FY2022 · CA

Radioimmunotherapy Combinations for B-cell Malignancy

$413,131
Damian J. Green · Fred Hutchinson Cancer Center · R01 · FY2023 · CA

EASTERN COOPERATIVE ONCOLOGY GROUP

$413,121
Vanderbilt University · U10 · FY2000 · CA

Reprogramming the Tumor Microenvironment in Ovarian Cancer

$413,104
David D Schlaepfer · University Of California, San Diego · R01 · FY2021 · CA

CLINICAL IMAGING AND RADIATION DOSIMETRY

$413,077
James R Bading · Beckman Research Institute/City Of Hope · P01 · FY2008 · CA

Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy

$413,046
Xiang-Yang Wang · Virginia Commonwealth University · R01 · FY2020 · CA

How IL-10R blockade can resolve persistent viral infections

$412,999
Matthias G. Von Herrath · La Jolla Institute For Immunology · R01 · FY2010 · AI

Oncolytic Virus Therapeutic Responses Occur from Changes in the Glioblastoma Immune Microenvironment

$412,964
E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2025 · NS

A Phase I Study of Lentivirus Safety During T-Cell Immu

$412,957
City Of Hope/Beckman Research Institute · P01 · FY2005 · AI

Biostatistics Facility

$412,921
Daniel P. Normolle · University Of Pittsburgh At Pittsburgh · P30 · FY2020 · CA

Project 2: Spatial Architecture of Tumor-Mediated Immunosuppression

$412,868
Garry P Nolan · Stanford University · U54 · FY2018 · CA

Allergen T cell epitopes and phenotypes during peanut immunotherapy

$412,840
Erik Wambre · Benaroya Research Inst At Virginia Mason · U19 · FY2018 · AI

Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure

$412,810
Mark W Jackson · Case Western Reserve University · R01 · FY2025 · CA

Unbiased electrothermal flow-enhanced identification of antigen-specific T cells in lung cancer

$412,768
Alexandre Reuben · University Of Tx Md Anderson Can Ctr · R21 · FY2023 · CA

Evaluation of T follicular regulatory cells as novel cellular targets of cancer immunotherapy

$412,739
Simon Eschweiler · University Of Tx Md Anderson Can Ctr · R37 · FY2025 · CA

Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy

$412,712
Ralph R Weichselbaum · University Of Chicago · R01 · FY2021 · CA

Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment

$412,687
E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2021 · NS

Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment

$412,687
E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2023 · NS

Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment

$412,687
E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2022 · NS

Functional interplay between Hippo and estrogen receptor ESR1

$412,680
Jing Yang · University Of California, San Diego · R01 · FY2024 · CA